IRIS UniCatt

Salutari, Vanda
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.933
AS - Asia 2.223
EU - Europa 1.642
Continente sconosciuto - Info sul continente non disponibili 504
SA - Sud America 402
AF - Africa 61
OC - Oceania 7
Totale 7.772
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.858
SG - Singapore 864
CN - Cina 679
DE - Germania 414
IT - Italia 335
BR - Brasile 315
VN - Vietnam 220
SE - Svezia 209
FR - Francia 163
IN - India 100
IE - Irlanda 92
GB - Regno Unito 79
UA - Ucraina 73
PL - Polonia 66
ID - Indonesia 61
JP - Giappone 54
RU - Federazione Russa 54
HK - Hong Kong 52
FI - Finlandia 48
BD - Bangladesh 37
CA - Canada 37
AR - Argentina 35
TR - Turchia 27
IQ - Iraq 24
KR - Corea 24
NL - Olanda 24
ZA - Sudafrica 22
MX - Messico 19
AT - Austria 15
BE - Belgio 14
PK - Pakistan 14
CO - Colombia 12
EC - Ecuador 12
VE - Venezuela 11
SA - Arabia Saudita 10
CH - Svizzera 8
PY - Paraguay 8
KZ - Kazakistan 7
LT - Lituania 7
MA - Marocco 7
CI - Costa d'Avorio 6
CZ - Repubblica Ceca 6
KE - Kenya 6
AU - Australia 5
CL - Cile 5
ES - Italia 5
MY - Malesia 5
AL - Albania 4
DZ - Algeria 4
GE - Georgia 4
IL - Israele 4
IR - Iran 4
JO - Giordania 4
RO - Romania 4
TN - Tunisia 4
AZ - Azerbaigian 3
EG - Egitto 3
HU - Ungheria 3
JM - Giamaica 3
OM - Oman 3
PH - Filippine 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AW - Aruba 2
BG - Bulgaria 2
BS - Bahamas 2
CR - Costa Rica 2
ET - Etiopia 2
GA - Gabon 2
GR - Grecia 2
HN - Honduras 2
KG - Kirghizistan 2
LB - Libano 2
LV - Lettonia 2
MK - Macedonia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PE - Perù 2
PS - Palestinian Territory 2
SN - Senegal 2
TJ - Tagikistan 2
TW - Taiwan 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
BZ - Belize 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
IM - Isola di Man 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MT - Malta 1
NG - Nigeria 1
NP - Nepal 1
Totale 7.263
Salva come PNG Salva come JPEG
Città #
Singapore 457
San Jose 292
Ashburn 281
Chandler 249
Hangzhou 185
Beijing 138
Dublin 92
Ho Chi Minh City 73
New York 72
Los Angeles 63
Hefei 58
Hyderabad 56
Rome 56
Warsaw 56
San Mateo 54
Hanoi 53
Jakarta 53
Lauterbourg 52
Milan 48
Wilmington 48
Ann Arbor 46
Tokyo 46
Hong Kong 44
Jacksonville 44
Frankfurt am Main 43
Dallas 40
Munich 38
Redmond 33
Boston 31
Nanjing 31
Santa Clara 30
Moscow 29
The Dalles 29
Bar Harbor 28
Houston 27
São Paulo 26
Bremen 25
Atlanta 24
Dearborn 24
Cattolica 23
Helsinki 22
Chicago 21
Council Bluffs 21
Kent 21
Princeton 21
Nürnberg 20
Fairfield 19
Naples 19
Phoenix 19
Buffalo 18
Seoul 18
Johannesburg 17
Redwood City 17
St Louis 17
Seattle 16
Orem 14
Boardman 13
Brooklyn 13
Marseille 13
Nanchang 13
Woodbridge 13
Izmir 12
Lawrence 12
Paris 12
Shenyang 12
Denver 11
Brussels 10
Chennai 10
Dhaka 10
Haiphong 10
London 10
Washington 10
Düsseldorf 9
Rio de Janeiro 9
Shanghai 9
Vienna 9
Cambridge 8
Da Nang 8
Jiaxing 8
Amsterdam 7
Guangzhou 7
Kunming 7
Manchester 7
Mexico City 7
Montreal 7
Mountain View 7
San Francisco 7
Stockholm 7
Toronto 7
University Park 7
Zhengzhou 7
Abidjan 6
Baghdad 6
Bologna 6
Brasília 6
Campinas 6
Detroit 6
Falkenstein 6
Nairobi 6
New Haven 6
Totale 3.779
Salva come PNG Salva come JPEG
Nome #
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 526
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial 369
Early detection of recurrence or progression disease in patients with ovarian cancer after primary debulking surgery: a diagnostic challenge still unresolved. Correlation between CT findings and CA 125 levels. 364
Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence 322
Paclitaxel, epirubicin, and cisplatin (TEP) regimen as neoadjuvant treatment in locally advanced cervical cancer: long-term results 238
Stereotactic Ablative Radiation Therapy for Oligometastatic Ovarian Cancer Lymph Node Disease: The MITO-RT3/RAD Phase II Trial 202
A preliminary Quality Control (QC) for next generation sequencing (NGS) library evaluation turns out to be a very useful tool for a rapid detection of BRCA1/2 deleterious mutations 194
Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. 185
Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study 163
The 'lead vessel': a vascular ultrasound feature of metastasis in the ovaries. 151
Advanced and recurrent endometrial cancer: State of the art and future perspectives 145
Successful multimodal treatment of a breast cancer patient with a recurrence invading the chest wall 144
Concomitant boost dose escalation plus large-field preoperative chemoradiation in locally advanced carcinoma of the uterine cervix: results of a phase I study (LARA-CC-1). 143
"Occult" ovarian Leydig cell tumor: when laboratory tells more than imaging 143
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 142
Stereotactic radiotherapy in recurrent gynecological cancer: a case series 141
Optimizing treatment in recurrent epithelial ovarian cancer 137
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 128
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 126
PARP Inhibitors Resistance: Mechanisms and Perspectives 125
Recent progress in the use of pharmacotherapy for endometrial cancer 124
Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence 123
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer 121
Successful multimodal treatment of a breast cancer patient with a recurrence invading the chest wall 118
Immunotherapy-related imaging findings in patients with gynecological malignancies: What radiologists need to know 117
Medi-Cinema: A Pilot Study on Cinematherapy and Cancer as A New Psychological Approach on 30 Gynecological Oncological Patients 117
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 114
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 112
New medical approaches in advanced ovarian cancer 112
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials 110
Medi-Cinema: A Pilot Study on Cinematherapy and Cancer as A New Psychological Approach on 30 Gynecological Oncological Patients 106
Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor: A Single-Institution Experience (ID: PARROT Trial) 104
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 103
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study 103
Controversy in treatment of advanced ovarian cancer 102
Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study 102
Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8,MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study 102
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 100
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 99
Newly diagnosed ovarian cancer: Which first-line treatment? 98
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 96
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 94
Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: A retrospective single-center experience 92
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinumbased chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer 90
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 86
Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: A phase II, open label multicenter study (NUVOLA trial) 84
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere 83
Radical Surgery in Advanced Cervical Cancer Patients Receiving Bevacizumab-Containing Chemotherapy: A "Real Life Experience" 83
Combining targeted therapies in ovarian cancer 82
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 81
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 81
A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters: A multicentric Italian experience 79
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26) 78
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 74
Management of early-stage ovarian cancer: Open questions and debated issues 55
Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective Study 52
Lifestyle and environmental factors in women carrying BRCA pathogenic variants with and without cancer 49
Treatment of Oligometastatic Parenchymal Lesions in Ovarian Cancer With Stereotactic Ablative Radiation Therapy: A Multicenter Prospective Phase 2 Trial (MITO RT3/RAD) 46
Homologous recombination deficiency in Ovarian cancer: The game-changer for first-line maintenance therapy 25
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 20
Concordance Analysis of Microsatellite Instability via NGS and Mismatch Repair Deficiency via IHC in Endometrial and Colorectal Cancer 17
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 11
Ovarian cancer treatments strategy: Focus on parp inhibitors and immune check point inhibitors 9
Co-targeting hallmarks of cancer for therapeutic benefit in ovarian cancer: a scoping review 8
Immunotherapy in gynecological cancers 6
Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18) 6
Tisotumab Vedotin in Cervical Cancer: Current Status and Future Perspectives 5
Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art 5
Totale 7.772
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.161
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.161
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022231 0 0 2 15 17 6 3 60 5 13 54 56
2022/2023722 67 98 46 104 58 93 27 50 94 20 41 24
2023/2024511 20 131 29 35 18 82 48 15 4 20 53 56
2024/20251.086 28 17 82 39 71 38 40 46 155 135 235 200
2025/20262.769 343 100 224 349 430 171 403 157 226 204 93 69
2026/2027744 168 461 115 0 0 0 0 0 0 0 0 0
Totale 7.772